{"id":"NCT00550238","sponsor":"ACADIA Pharmaceuticals Inc.","briefTitle":"A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","officialTitle":"A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2018-05-30","completion":"2018-05-30","firstPosted":"2007-10-29","resultsPosted":"2019-06-24","lastUpdate":"2019-06-24"},"enrollment":459,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease Psychosis"],"interventions":[{"type":"DRUG","name":"Pimavanserin tartrate (ACP-103)","otherNames":[]}],"arms":[{"label":"Pimavanserin tartrate (ACP-103)","type":"EXPERIMENTAL"}],"summary":"To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.","primaryOutcome":{"measure":"Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs)","timeFrame":"From first to last study drug dose plus 30 days","effectByArm":[{"arm":"Pimavanserin","deltaMin":180,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":135,"countries":["United States","Austria","Belgium","Canada","France","India","Italy","Poland","Portugal","Russia","Serbia","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["28493654","26239690"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":188,"n":459},"commonTop":["Fall","Urinary tract infection","Hallucination","Weight decreased","Confusional state"]}}